Announcement on Subsidiary Companies Participating in the Fourth Batch of National Drug Centralized Procurement to be Bwon
Release time:
2021-05-20
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Lin 2021-003
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Subsidiaries Participating in the Fourth Batch of National Centralized Drug Procurement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
On February 3, 2021 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Group" or "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), participated in the fourth batch of national centralized drug procurement bids organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"), peak Pharmaceutical's Olopatadine Hydrochloride Eye Drops is proposed to win the bid for this centralized procurement. The relevant information is hereby announced as follows:
Basic Situation of 1. Proposed Winning Products
Proposed Winning Products |
Specifications |
Indications |
Proposed Winning Price |
Proposed Winning Quantity |
Provinces |
Olopatadine Hydrochloride Eye Drops |
5ml:5mg (0.1%) |
is suitable for treating signs and symptoms of allergic conjunctivitis |
19.9 yuan/ box |
36.23 box |
Shanghai, Zhejiang, Guangdong, Sichuan, Henan, Liaoning, Hubei, Chongqing, Hunan, Shaanxi, Anhui, Hainan, Xinjiang (including bingtuan), Jiangxi, Qinghai, Tibet |
the bid price and the bid quantity of the above varieties are subject to the final data released by the joint procurement office. According to the relevant winning rules, the bid period for this bid is 1 year.
The impact of 2.'s proposed winning the bid on the company
Jianfeng Pharmaceutical's proposed winning product Olopatadine Hydrochloride Eye Drops obtained the approval of State Drug Administration and issued Drug Registration Approval Document in 4 in 2019 . The market sales volume of was relatively small before , the sales revenue of this product in 2019 and 2020 1-9 September are 5.65 .01 million yuan and 97.74 .03 million yuan respectively, accounting for 2019 annual operating revenue 354 respectively, 753.76 .07 million yuan of 0.0016% and 2020 1-9 March operating income 224,065.44 .15 million yuan of 0.04% .
This centralized procurement is the fourth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to the drugs selected in this centralized drug procurement and ensure the completion of the agreed procurement volume. The price of the products to be selected this time has decreased to a certain extent compared with the original price. If the company subsequently signs a purchase contract and implements it, it will help expand the sales scale of the product, increase market share, and enhance the company's brand influence, which has a positive impact.3. Risk Alert
At present, the company has signed the "Memorandum of National Drug Centralized Procurement of Selected Varieties" with the Joint Procurement Office. There is still uncertainty about the follow-up matters such as the signing of the purchase agreement for the above products and the impact on the company's future performance. The company will pay close attention to the progress of the matter and timely discharge of information disclosure obligations, so that the majority of investors cautious decision-making, pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
February 5, 2001
More information
The company won the Taurus Award
On December 29, 2022, the "2022 High-quality Development Forum of listed companies and the 24th Golden Bull Award presentation ceremony of listed companies" jointly sponsored by China Securities News, Haikou Municipal Government and Haikou National High-tech Zone was held in Haikou. The list of Golden Bull Awards of listed companies was officially announced. With its outstanding performance, Jianfeng Group won the "2021 Golden Bull Most Investment Value Award".
2023
01-12
From December 11th to 12th, the 13th National Congress of the All-China Federation of Industry and Commerce was held in Beijing. Jiang Xiaomeng, chairman of the group company, attended the conference as a representative of Zhejiang.
2022
12-22
Yunnan Jianfeng won the title of "Harmonious Labor Relations Enterprise" in Yunnan Province
On November 18, the Yunnan Provincial Federation of Trade Unions, the Department of Human Resources and Social Security, the Entrepreneur Association and other units jointly issued a document to commend the harmonious labor relations enterprises in Yunnan Province from 2020 to 2021. Yunnan Jianfeng Cement Company is on the list and is the only enterprise in the urban area of Pu'er to receive this honor.
2022
12-13
Huang Ping Jianfeng won the title of "provincial green factory" in Guizhou
On November 30, the Guizhou Provincial Department of Industry and Information Technology released the 2022 list of green manufacturing units in Guizhou Province, and Huangping Jianfeng Cement Company was recognized as a "provincial green factory".
2022
12-13
On December 2, Yu Jianhong, general manager of the group company, gave a management lesson to the company's reserve management talents under the title of "Enterprise Management Innovation in Great Changes.
2022
12-13
On November 24, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, gave a special party lesson to all party members and cadres of the company under the title of "comprehensively promoting the Great Rejuvenation of the Chinese Nation with Chinese Modernization" to interpret and preach the spirit of the 20th CPC National Congress.
2022
12-04